Paclitaxel and carboplatin in bladder cancer: recent developments

Paclitaxel demonstrates significant single-agent activity in advanced uroth elial carcinoma. Paclitaxel/carboplatin is an active and tolerable outpatie nt chemotherapy treatment regimen for these patients. This regimen has been studied in several phase II trials with response rates ranging from 14 to 65%. Paclitaxel/carboplatin may be considered in patients with advanced uro thelial cancer and renal insufficiency, and a recent Eastern Cooperative On cology Group (ECOG) phase II trial investigates this regimen specifically i n this patient population. Ongoing ECOG trials are comparing paclitaxel/car boplatin with M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) in both the advanced disease and adjuvant settings. (C) 2000 Published by Else vier Science Ltd. All rights reserved.